NCT02642042 2026-03-04Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting60 enrolled 24 charts
NCT03225664 2026-01-16Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting37 enrolled